No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines

International Journal of Radiation Biology

Volumn 75, Issue 9, 1999, Pages 1149-1160

  Danielsen, T ^a   Smith Sorensen B ^a   Gronlund H A ^a   Hvidsten, M ^a   Borresen Dale A L ^a   Rofstad, E K ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN P53; RAF PROTEIN; RAS PROTEIN;

ARTICLE; CELL CYCLE PARAMETERS; CELL LEVEL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; MELANOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CELL HYPOXIA; DNA-BINDING PROTEINS; G1 PHASE; HUMANS; MELANOMA; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS C-RAF; RADIATION TOLERANCE; RAS PROTEINS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0032852871     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530099139629     Document Type: Article

References (62)

1. AHMED, M. M., VENKATASUBBARAO, K., FRUITWALA, S. M., MUTHUKKUMAR, S., WOOD, D. P. J., SELLS, S. F., MOHIUDDIN, M. and RANGNEKAR, V. M., 1996 EGR-I induction is required for maximal radiosensitivity in A375-C6 melanoma cells. Journal of Biological Chemistry, 271, 29231-29237.
2. ANDERSEN, T. I. and BORRESEN, A. L., 1995, Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagnostic Molecular Pathology, 4, 203-211.
3. BALCER-KUBICZEK, E. K., YIN, J., LIN, K., HARRISON, G. H., ABRAHAM, J. M. and MELTZER, S.J., 1995, p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons. Radiation Research, 142, 256-262.
4. BARLOW, C., BROWN, K. D., DENG, C.-X., TAGLE, D. A. and WYNSHAW-BORIS, A., 1997, Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nature Genetics, 17, 453-456.
5. BARTKOVA, J., LUKAS, J., GULDBERG, P., ALSNER, J., KIRKIN, A. F., ZEUTHEN, J. and BARTEK, J., 1996, The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Research, 56, 5475-5483.
6. BIARD, D. S., MARTIN, M., RHUN, Y. L., DUTHC, A., LEFAIX, J. L., MAY, E. and MAY, P., 1994, Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Research, 54, 3361-3364.
7. BORRESEN, A.-L., 1996, Constant denaturant gel electrophoresis (CDGE) in mutation screening. In G. P. Pfeifer (ed.), Technologies for Detection of DNA Damage and Mutation (New York: Plenum), pp. 267-279.
8. BRACHMAN, D. G., BECKETT, M., GRAVES, D., HARAF, D., VOKES, E. and WEICHSELBAUM, R. R., 1993, p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Research, 53, 3667-3669.
9. BRISTOW, R. G., BENCHIMOL, S. and HILL, R. P., 1996, The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology, 40, 197-223.
10. CASSONT, A. M., 1994, Oncogenes and radiosensitivity. European Journal of Cancer, 30A, 279-281.
11. CASTELLANO, M., POLLOCK, P. M., WALTERS, M. K., SPARROW, L. E., DOWN, L. M., GABRIELLI, B. G., PARSONS, P. G. and HAYWARD, N. K., 1997, CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Research, 57, 4868-4875.
12. DANIELSEN, T., HVIDSTEN, M., STOKKE, T., SOLBERG, K. and ROFSTAD, E. K., 1998, Hypoxia induces p53 accumulation in the S phase and accumulation of hypophosphorylated retinoblastoma protein in all cell cycle phases of human melanoma cells. British Journal of Cancer, 78, 1547-1558.
13. DANIELSEN, T., SKOYUM, R. and ROFSTAD, E. K., 1997, Hypoxia-induced changes in radiation sensitivity in human melanoma cells: importance of oxygen-regulated proteins, adenylate energy charge and cell cycle distribution. Radiotherapy and Oncology, 44, 177-182.
14. DEAGON, J., PECKHAM, M. J. and STEEL, G. G., 1984, The radioresponsiveness of human tumours and the initial slope of cell survival curve. Radiotherapy and Oncology, 2, 317-323.
15. FERTH, B. and MALAISE, E. P., 1981. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 7, 621-629.
16. GENG, L., WALTER, S., MELIAN, E. and VAUGHAN, A. T. M., 1998, Transfection of a vector expressing wild-type p53 into cells of two human glioma cell lines enhances radiation toxicity. Radiation Research, 150, 31-37.
17. GRUIS, N. A., WEAVER-FELDHAUS, J., LIU, Q., FRYE, C., EELES, R., ORLOW, I., LACOMBE, L., PONCE-CASTANEDA, V., LIANES, P., LATRES, E., SKOLNICK, M., CORDON-CARDO, C. and KAMB, A., 1995, Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. American Journal of Pathology, 146, 1199-1206.
18. HABERMALZ, H. J., 1981, Irradiation of malignant melanoma: experience in the past and present. International Journal of Radiation Oncology, Biology, Physics, 7, 131-133.
19. HARTMANN, A., BLASZYK, H., CUNNINGHAM, J. S., McGOVERN, R. M., SCHROEDER, J. S., HELANDER, S. D., PRITTELKOW, M. R., SOMMER, S. S. and KOVAGH, J. S., 1996, Overexpression and mutations of p53 in metastatic malignant melanoma. International Journal of Cancer, 67, 313-317.
20. HARWOOD, A. R. and CUMMINGS, B. J., 1981, Radiotherapy for malignant melanoma: a re-appraisal. Cancer Treatment Reviews. 8, 271-282.
21. HOVIG, E., SMITH-SORENSEN, R., BROGGER, A. and BORRESEN, A. L., 1991, Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. Mutation Research, 262, 63-71.
22. HUANG, H., LI, C. Y. and LITTLE., J. B., 1996, Abrogation of P53 function by transfection of HPV16 E6 gene does not enhance resistance of human tumour cells to ionizing radiation, International Journal of Radiation Biology, 70, 151-160.
23. KASID, U., PFEIFER, A., BRENNAN, T., BECKETT, M., WEIGHSELBAUM, R. R., DRITSCHILO, A. and MARK, G. E., 1989. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. Science, 243, 1354-1356.
24. KO, L.J. and PRIVES, C., 1996, p53: puzzle and paradigm, Genes and Development, 10, 1054-1072.
25. KWOK, T. T. and SUTHERLAND, R. M., 1989, Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. Journal of the National Cancer Institute, 81, 1020-1024.
26. LAEMMLI, U. K., 1970, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227, 680-685.
27. LANE, D. P., 1992, p53, guardian of the genome. Nature, 358, 15-16.
28. LI, C. Y., NAGASAWA, H., DAHLBERG, W. K. and LITTLE, J. B., 1995, Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines. Oncogene, 11, 1885-1892.
29. LITTLE, J. B., NAGASAWA, H., KENG, P. C., YU, Y. and Lt, C. Y., 1995, Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. Journal of Biological Chemistry, 270, 11033-11036.
30. MATSUMURA, Y., YAMAGISHI, N., MIYAKOSHI, J., IMAMURA, S. and TAKEBE, H., 1997. Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. Cancer Letters, 115, 91-96.
31. MCILWRATH, A. J., VASEY, P. A., ROSS, G. M. and BROWN, R., 1994. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Research, 54, 3718-3722.
32. McMILLAN, T.J. and PEACOCK, J. H., 1994, Molecular determinants of radiosensitivity in mammalian cells. International Journal of Radiation Biology, 65, 49-55.
33. MILLER, A. C., KARIKO, K., MYERS, C. E., CLARK, E. P. and SAMID, D. 1993, Increased radioresistance of EJras-transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation. International Journal of Cancer, 53, 302-307.
34. MORGAN, S. E. and KASTAN, M. B., 1997, p53 and ATM: cell cycle, cell death, and cancer, Advances in Cancer Research, 71, 1-25.
35. NAGASAWA, H., LI, C. Y., MAKI, C. G., IMRICH, A. C. and LITTLE, J. B., 1995, Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Research, 55, 1842-1846.
36. O'CONNOR, P. M., JACKMAM, J., JONDLE, D., BHATIA, K., MAGRATH, I. and KOHN, K. W., 1993, Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Research, 53, 4776-4780.
37. POMP, J., OUWERKERK, I. J., HERMANS, J., WONDERGEM, J., CORNELISSE, C.J., LEER, J. W. and SCHRIER, P. I., 1996, The influence of the oncogenes NRAS and MYC on the radiation sensitivity of cells of a human melanoma cell line. Radiation Research, 146, 374-381.
38. RIBEIRO, J. C., BARNETSON, A. R., FISHER, R. J., MAMEGHAN, H. and RUSSELL, P. J., 1997, Relationship between radiation response and p53 status in human bladder cancer cells. International Journal of Radiation Biology, 72, 11-20.
39. ROFSTAD, E. K., 1986, Radiation biology of malignant melanoma. Acta Radiologica Oncology, 25, 1-10.
40. ROFSTAD, E. K., 1989, Local tumor control following single dose irradiation of human melanoma xenografts: relationship to cellular radiosensitivity and influence of an immune response by the athymic mouse. Cancer Research, 49, 3163-3167.
41. ROFSTAD, E. K., 1992a, Retention of cellular radiation sensitivity in cell and xenograft lines established from human melanoma surgical specimens. Cancer Research, 52, 1764-1769.
42. ROFSTAD, E. K., 1992b, Comparative sensitivity of cells from human tumors and derivative tumor xenografts to radiation and heat treatments. Journal of the National Cancer Institute, 84, 1517-1524.
43. ROFSTAD, E. K., 1994a, Orthotopic human melanoma xenograft model systems For studies of tumour angiogenesis, pathophysiology, treatment sensitivity and metastatic pattern. British Journal of Cancer, 70, 804-812.
44. ROFSTAD, E. K., 1994b, Fractionation sensitivity (α/β ratio) of human melanoma xenografts. Radiotherapy and Oncology, 33, 133-138.
45. ROFSTAD, E. K. and BRUSTAD, T., 1981, Radiation response in vitro of cells from five human malignant melanoma xenografts. International Journal of Radiation Biology, 40, 677-680.
46. ROFSTAD, E. K., WAHL, A. and BRUSTAD, T., 1987, Radiation sensitivity in vitro of cells isolated from human tumor surgical specimens. Cancer Research, 47, 106-110.
47. RYGAARD, K., SLEBOS, R. J. and SPANG-THOMSEN, M., 1991, Radiosensitivity of small-cell lung cancer xenografts compared with activity of c-myc, N-myc, L-myc, c-raf-1 and K-ras proto-oncogenes. International Journal of Cancer, 49, 279-284.
48. SAUTER, E. R., COTA, L. R., EISENBERG, B. L. and RIDGE, J. A., 1994, Radiation treatment decreases transforming growth factor alpha expression in squamous carcinoma of the tongue. Cancer Letters, 78, 159-162.
49. SERRANO, M., HANNON, G. J. and BEACH, D., 1993, A new regulatory motif in cell-cycle control causing specific, inhibition of cyclin D/CDK4. Nature, 366, 704-707.
50. SERVOMAA, K., KIURU, A., GRENMAN, R., PEKKOLA-HEINO, K., PULKKINEN, J. O. and RYTOMAA, T., 1996, p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Proliferation, 29, 219-230.
51. SILES, E., VILLALOBOS, M., VALENZUELA, M. T., NUNEZ, M. I., GORDON, A., McMILLAN, T. J., PEDRAZA, V. and RUTZ, D. A. M., 1996, Relationship between p53 status and radiosensitivity in human tumour cell lines. British Journal of Cancer, 73, 581-588.
52. SMITH-SORENSEN, B., KæRN, J., HOLM, R., DOØRUM, A., TROPÉ, C. and BØRRESEN-DALE, A.-L., 1998. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. British Journal of Cancer, 78, 375-381.
53. STEEL, G. G., DEACON, J. M., DUGHESNE, G. M. HORWICH, A., KELLAND, L. R. and PEACOCK, J. H., 1987, The dose-rate effect in human tumour cells. Radiotherapy and Oncology, 9, 299-310.
54. 1 checkpoint control is an early step in carcinogenesis, independent of p53 status. Cancer Research, 59, 1008-1014.
55. THOMAS, C. P., BURONFOSSE, A., COMBARET, V., PEDRON, S., FERTIL, B, and PORTOUKALIAN, J., 1996, Gangliosides protect human melanoma cells from ionizing radiation-induced clonogenic cell death. Glycoconjugate Journal, 13, 377-384.
56. WARENIUS, H. M., BROWNING, P. G., BRITTEN, R. A., PEACOCK, J. A. and RAPP, U. R., 1994, C-raf-1 proto-oncogene expression relates to radiosensitivity rather than radioresistance. European Journal of Cancer, 30A, 369-375.
57. WATERMAN, M. J. F., STAVRIDI, E. S., WATERMAN, J. L. F. and HALAZONETIS, T. D., 1998, ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genetics, 19, 175-178.
58. WATSON, N. C., DI, Y.-M., ORR, M. S., FORNARI, JR F. A., RANDOLPH, J. K., MAGNET, K. J., JAIN, P. T. and GEWIRTZ, D. A., 1997, Influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumour cell lines differing in p53 status. International Journal of Radiation Biology, 72, 547-559.
59. WEICHSELBAUM, R. R., HALLAHAN, D., FUKS, Z. and KUFE D., 1994, Radiation induction of immediate early genes: effectors of the radiation-stress response. International Journal of Radiation Oncology, Biology, Physics, 30, 229-234.
60. WEISS, J., SCHWECHHEIMER, K., CAVENEE, W. K., HERLYN, M. and ARDEN, K. C., 1993, Mutation and expression of the p53 gone in malignant melanoma cell lines. International Journal of Cancer, 54, 693-699.
61. WEST, C. M., DAVIDSON, S. E., ROBERTS, S. A. and HUNTER, R. D., 1997, The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. British Journal of Cancer, 76, 1184-1190.
62. YOUNT, G. L., HAAS-KOGAN, D. A., VIDAIR, C. A., HAAS, M., DEWEY, W. C. and ISRAEL, M. A., 1996, Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Research, 56, 500-506.